Back
#1
25.7%
Top 0.3%
16.9%
Top 0.5%
9.0%
Top 0.2%
9.0%
Top 68%
7.4%
Top 0.3%
6.9%
Top 36%
4.5%
Top 76%
2.2%
Top 2%
1.8%
Top 0.9%
1.5%
Top 2%
1.4%
Top 8%
0.8%
Top 5%
0.8%
Top 21%
0.8%
Top 26%
0.5%
Top 0.8%
0.5%
Top 23%
0.5%
Top 37%
0.5%
Trends in Medicare Part D Spending on Antifibrotic Therapies for Pulmonary Fibrosis: 2019-2023
2025-08-02
respiratory medicine
Title + abstract only
View on medRxiv
Show abstract
BackgroundNintedanib and pirfenidone are antifibrotic agents approved for the treatment of idiopathic pulmonary fibrosis (IPF) and progressive fibrosing interstitial lung diseases. Despite their clinical significance, national trends in Medicare Part D spending and utilization for these therapies remain insufficiently characterized. ObjectiveTo evaluate national trends in Medicare Part D spending, claims, and cost-per-claim for nintedanib and pirfenidone from 2019 to 2023. MethodsMedicare Part...
Predicted journal destinations
1
European Respiratory Journal
44 training papers
2
BMJ Open Respiratory Research
32 training papers
3
ERJ Open Research
36 training papers
4
Thorax
29 training papers
5
PLOS ONE
1737 training papers
6
American Journal of Respiratory and Critical Care Medicine
23 training papers
7
BMJ Open
553 training papers
8
Scientific Reports
701 training papers
9
Medicine
29 training papers
10
Journal of Allergy and Clinical Immunology
15 training papers
11
Frontiers in Pharmacology
27 training papers
12
JCI Insight
63 training papers
13
eClinicalMedicine
55 training papers
14
Frontiers in Medicine
99 training papers
15
Journal of Clinical Medicine
77 training papers
16
The Lancet Respiratory Medicine
16 training papers
17
PLOS Digital Health
88 training papers
18
JAMA Network Open
125 training papers